Cardiol Therapeutics Soars 14.41% on Buy Signal

On August 14, 2025, Cardiol Therapeutics' stock surged by 14.41% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Cardiol Therapeutics has recently received a buy signal from a pivot bottom point, which has contributed to its upward momentum. This signal, issued on August 8, 2025, has already resulted in a 10% increase in the stock price, indicating strong investor confidence in the company's prospects.

Analysts have also shown optimism towards Cardiol Therapeutics. HC Wainwright initiated coverage on the company, assigning a "buy" rating with a price target of $9.00. This positive outlook reflects the company's potential for growth and its ability to deliver on its promises.

Additionally, Cardiol Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. This volatility can be attributed to the company's innovative approach to cardiovascular therapies, which has the potential to disrupt the market and drive significant returns for investors.